Portfolio Finder

4 Animals AlsterScience Exit

4 Animals AlsterScience GmbH develops innovative therapies for animals. Through targeted use of natural immunomodulators immune function is significantly improved and in sick and old animals optimally restored.

HTGF-Manager: Ulrike Kalapis
In portfolio 03. Jul 2014 – 09. Dec 2020


4GENE offers its FLAVOR-ON-DEMAND technology platform of activatable flavor and fragrance glucosides to its Customers in the Cosmetics, Food and Industrial Application Market Segments. 4GENE is a biotech start-up company founded at the Professorship for Biotechnology of Natural Products led by Prof. Dr. Wilfried Schwab at the Technical University Munich. During the EXIST Funding Program 4GENE cooperated with Prof. Dr.-Ing. Ralf Takors, Head of the Institute for Biotechnical Engineering at the University of Stuttgart to provide the Proof-of-Concept for the production of flavor glucosides. Today the company has 8 Employees and operates from Offices in Freising and Stuttgart in Germany with its customers worldwide.


8sense is a platform of virtual coaching systems consisting of sensor technology and a mobile app in the healthcare sector. 8sense helps companies to save healthcare costs and private individuals to reach their better and healthier me. The company is currently developing a system to combat back pain. 8sense primarily acts as a system provider (B2B), but the coaching systems can also be purchased by the end customer (B2C).

Website: 8sense.com
HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 01. Feb 2019


Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.

HTGF-Manager: Dr. Frank Hensel
Added to portfolio 10. Jul 2019


adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 19. Jul 2018


AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biologic drugs in acute vascular syndromes and have completed phase 2.

HTGF-Manager: Marco Winzer
Added to portfolio 25. Jun 2014


ADVANOVA was founded in January 2012 by Dr. Frank Hemer, a doctor and computer scientist, and Bastian Bleisinger, a computer scientist. The company’s head office is in Erlangen at the centre of Germany’s “Medical Valley”.

HTGF-Manager: Kay G. Balster
Added to portfolio 17. Dec 2012


Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).

Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from the University of Strasbourg and Inserm, the French National Institutes of Health and the Mount Sinai Hospital, New York.

The portfolio is based on profound knowledge and expertise in liver disease, unique patient-derived model systems and the discovery of a novel, very fundamental mechanism of action underlying these diseases.

Alentis has lead monoclonal antibodies which show consistent compelling efficacy and safety in patient-derived cell and animal models.

Furthermore, Alentis has a proprietary discovery platform enabling fast-track discovery and development of compounds and targets that are relevant in the pathology of late stage liver disease and carcinogenesis.

Website: alentis.ch
HTGF-Manager: Dr. Frank Hensel
Added to portfolio 12. Apr 2019


Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.

HTGF-Manager: Dr. Martin Pfister
Added to portfolio 13. Jan 2012

Amedrix Exit

Amedrix develops & produces three dimensional implants (gel and liquid) based on collagen. Focus: treatment of articular cartilage damage in human an horse and other promising application areas. CE-mark for the cartilage repair product is granted & successfully used in patients.

Sector: Life Sciences
HTGF-Manager: Dr. Martin Pfister
In portfolio 01. Dec 2009 – 15. Jul 2013


Angiolutions specializes in device-based innovation in vascular medicine. Through its latest award-winning technology, the company aims to prevent the deadly progression of small abdominal aortic aneurysms.
An abdominal aortic aneurysm is a bulging of the abdominal aorta. With a growing aneurysm diameter, the risk of fatal rupture increases. While this progressive disease affects a substantial number of patients worldwide, there is no therapy available to stop aneurysm growth. Based on latest research findings, that the founding team acquired during its academic work, Angiolutions aims to stop aneurysm progression at an early stage.

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 09. Dec 2020

AQ Implants Exit

The core competency of AQ Implants GmbH is the endoprosthetic reconstruction of severe and complex defects and anomalies. With the development of innovative implant systems AQ Implants GmbH provides surgeons with various surgical options to reconstruct a wide variety of defects.

Under the brand name REVISIO they offer a complete range of implants for the treatment of revision and tumour cases, from easy revision cases to modular-complex defect treatments.

Sector: Life Sciences
HTGF-Manager: Dr. Martin Pfister
In portfolio 29. Aug 2011 – 18. May 2012


Atriva Therapeutics stands for the next generation of antiviral therapies. MEK Inhibitors have high potential as truly efficacious and safe antiviral drugs to address the urgent need e.g. for a novel, broadly active influenza therapy.

HTGF-Manager: Dr. Frank Hensel
Added to portfolio 27. Dec 2016


AudioCure Pharma specializes in the preclinical and clinical development of small molecules for the treatment of audiological and neurodegenerative diseases like sudden hearing loss, tinnitus, Parkinson’s and Alzheimer’s disease. In a first step the company focuses on sudden hearing loss.

Our compounds AC102 and AC002 have shown excellent efficacy in different animal models for the above-mentioned indications. Consequently, AudioCure is on its way to perform formal preclinical tests and to move AC102 into first-in-man testing.

HTGF-Manager: Dr. Martin Pfister
Added to portfolio 20. Apr 2012


Modern therapeutic approaches face the challenge to combine efficacy, low undesired side effects and reasonable pricing. Therefore, drug substances become more and more complex, therapies become more personalized while overall life-cycle costs from drug discovery up to the manufacturing of the final therapeutic are on trial.
Peptides – or short proteins - represent a promising therapeutic class, and Belyntic’s PEC technology offers an innovative solution for their manufacturing. The linker-based approach enables parallel, efficient and highly selective purification and modification of chemically synthesized peptides. Belyntic offers kit products as well as cooperation projects and custom services for research institutions, custom peptide manufacturers as well as biotech and pharma companies.

Sector: Life Sciences
HTGF-Manager: Ulrike Kalapis
Added to portfolio 08. Apr 2019


BOMEDUS GmbH is an innovative start-up company in the field of medical devices. Based on latest neurophysiological insights BOMEDUS is developing a combined platform technology that can be integrated into a wide range of consumer products.

Website: bomedus.com
HTGF-Manager: Kay G. Balster
Added to portfolio 17. Apr 2012

c-LEcta Exit

c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either as in-house development or in close cooperation with the industry. c-LEcta innovation capability delivers cost-efficient and sustainable production processes, creating growth opportunities across existing and new markets.

HTGF-Manager: Marco Winzer
In portfolio 19. Jan 2006 – 15. Feb 2022


Capical is the world leading company for contact-free ECG-measurement via capacitive electrodes. The main application areas are drivers state monitoring for the automotive industry and contact-free cardiac monitoring solutions for medical applications.

HTGF-Manager: Kay G. Balster
Added to portfolio 27. Jul 2011


Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept (POC) data.

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 03. May 2017


CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced treatment of various neurological and psychiatric disorders. The CereGate platform is able to transmit information into the brain („Mind-Writing“), by utilizing state of the art neuromodulation technology. While focusing first on improving gait symptoms for Parkinson patients, CereGate aims to become a key enabling tech¬nology in the field of rehabilitation and (neuro)prosthetics.

HTGF-Manager: Kay G. Balster
Added to portfolio 06. Dec 2019


coramaze technologies GmbH, based in Munich, Germany and founded in 2013 as a University Hospital of Essen spin-off, is engaged in developing an innovative Mitral Valve repair system - mitramaze® - for a minimally invasive transcatheter repair of mitral regurgitation (MR).

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 06. Feb 2014

Corimmun Exit

Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.

Exit since June 2012.

Sector: Life Sciences
HTGF-Manager: Marco Winzer
In portfolio 29. Dec 2006 – 22. Jun 2012


CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.

HTGF-Manager: Marco Winzer
Added to portfolio 12. Aug 2011


Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.

HTGF-Manager: Kay G. Balster
Added to portfolio 21. Dec 2009

Cunesoft Exit

Cunesoft provides pioneering online regulatory software for the life sciences and other regulated industries. The SaaS (Software as a Service) based solutions are delivered fully functional to customers and fulfill FDA, EU, ICH and GxP compliance regulations.

Sector: Life Sciences
HTGF-Manager: Dr. Bernd Goergen
In portfolio 16. Oct 2014 – 23. Dec 2019


Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible drug delivery system called the Langerhans Cell Targeted Delivery System (LC-TDS). With this technology, the company aims to realize innovative immunotherapies in conjunction with minimally invasive administration. As a spin-off of the Max Planck Institute of Colloids and Interfaces, Cutanos will demonstrate the full range of its platform technology from their headquarter in Austrian capital of Vienna, financed by an equally motivated investment consortium (including KHAN-I, HTGF and IST cube).

Sector: Life Sciences
HTGF-Manager: Dr. Julian Zachmann
Added to portfolio 23. Apr 2021


This innovative biotechnology company was founded in 2012 as a spin-out of the Institute for Molecular Microbiology and Biotechnology of the Westfälische Wilhelms-Universität in Münster. Cysal is active in the production of biopolymers, peptides, and especially dipeptides. Furthermore, Cysal specializes in developing biotechnology solutions in General.

Cytena Exit

cytena's single-cell printer is a unique device for separating, sorting and handling of single biological cells. For the first time this method enables an automated, separation of single cells with high viability and proof of clonality without cross-contamination risks.

Sector: Life Sciences
HTGF-Manager: Dr. Lena Krzyzak
In portfolio 13. Apr 2015 – 05. Aug 2019


denovoMATRIX develops and manufactures biomimetic coatings for the cultivation of human stem cells. Our focus is on enabling culture conditions for stem and primary cells closer to the natural conditions found in the body. Our products offer a biologically relevant solution, which is both chemically defined, and modular for adapting to specific applications. Our vision is to enable human biology in vitro, beginning with Life Science research and onwards to cell therapies of the future.

HTGF-Manager: Dr. Katharina Severin
Added to portfolio 15. Oct 2018

Draupnir Bio

Draupnir Bio is founded on the pillars of outstanding protein and carbohydrate chemistry. Its mission is to understand the molecular basis of how disease-risk proteins interact with carbohydrate structures of the vascular glycocalyx, and use this knowledge to develop therapeutics for life-threatening illnesses. The company is a spin out from Aarhus University, Denmark and Max Planck Institute, Potsdam, Germany.
The lead program is a small molecule oral available PCSK9 inhibitor for lowering LDL cholesterol. Its discovery is based on the finding that PCSK9-induced degradation of the LDL receptor requires the interaction of PCSK9 with distinct heparan sulfate structures of the liver glycocalyx. Inhibition of the PCSK9/heparan sulfate interaction protects the LDL receptor and allows it to remove LDL cholesterol from the blood, thereby preventing the progression of ischemic heart disease, the biggest killer worldwide.

HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 27. Dec 2018